Abstract
To evaluate the immunostimulatory activity of Efcovida powder, we induced immunosuppression in Swiss mice by cyclophosphamide (CP). Efcovida powder at two doses of 60 mg/kg b.w and 120 mg/kg b.w were administered orally for seven consecutive days to animals. CP (200 mg/kg i.p.) was injected on the 4th day. The result showed that Efcovida powder at the dose of 60 mg/kg b.w only posed an immunostimulating potency in the cyclophosphamide-induced immunosuppression model while Efcovida powder at the dose of 120 mg/kg b.w significantly ameliorated the effects of CP on delayed-type hypersensitivity (DTH) response, leukocyte quantity, relative thymus weight, serum IL-4, IL-6 concentration, and micro-histological images of spleen and thymus. This suggested the potential of Efcovida powder to treat immunosuppression diseases in clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
